Optimal Dose https://validator.w3.org/feed/docs/rss2.html GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC ENHERTU approved in Japan as first tumor agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumors ENHERTU now available in Japan as first ADC for the second-line treatment of patients with HER2 positive metastatic gastric cancer Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large b-cell lymphoma GSK’s B7-H3-targeted ADC, Risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation across an ADC clinical program Weekly News 21 March to 27 March 2026 Weekly News 21 March to 27 March 2026 Optimal Dose – CAR-T Digest (August 2020) Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016 Alphamab Oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was officially accepted by CDE Weekly News 14 March to 20 March 2026 Weekly News 14 March to 20 March 2026 Voro Therapeutics announced research collaboration with Daiichi Sankyo to advance PrimeBody™ technology for next-generation tumor-activated ADCs Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2 bispecific ADC JSKN027 3B Pharmaceuticals and TetraKit Technologies announce strategic collaboration for joint radioligand therapy (RLT) development Ifinatamab Deruxtecan receives U.S. Priority Review for previously treated extensive-stage SCLC progressing after platinum-based chemotherapy Weekly News 11 April to 17 April 2026 Weekly News 11 April to 17 April 2026 CSPC Pharmaceutical Group Limited obtains NMPA clinical trial approval for TF-targeted ADC SYS6051 in China CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload ADCs GlycoNex receives PMDA approval in Japan to initiate first-in-human phase 1 trial of GNX1021 in gastrointestinal cancers Disitamab Vedotin approved in china as first line therapy for HER2 expressing urothelial carcinoma AstraZeneca initiates Phase 3 CLARITY-Gastric 02 trial of AZD0901 combo in CLDN18.2+ gastric cancer Weekly News 07 March to 13 March 2026 Weekly News 07 March to 13 March 2026 Fujifilm Invests in VALANX Biotech to Strengthen ADC CDMO Capabilities Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio ProstACT Global Phase 3 study (part 1) achieves primary objectives Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer Weekly News 04 April to 10 April 2026 Weekly News 04 April to 10 April 2026 Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in second-line HNSCC and cervical cancer Akari Therapeutics announces strategic partnership with WuXi XDC to advance development of its novel ADC payload targeting RNA splicing The New Drug Application (NDA) for DB-1303/BNT323 for unresectable or metastatic HER2-positive adult breast cancer has been accepted by the NMPA Sidewinder Therapeutics announces $137 million series B financing to advance precision bispecific ADCs into clinical development for cancer Celltrion ADC drug candidate CT-P71 receives FDA Fast Track Designation for urothelial carcinoma NextCure receives Fast Track Designation for SIM0505 (CDH6 ADC) in ovarian cancer Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, Zocilurtatug Pelitecan, in combination with a bispecific T-cell Engager therapy RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials Weekly News 28 March to 03 April 2026 Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC Weekly News 28 March to 03 April 2026 ENHERTU followed by THP approved in China as the first and only HER2 directed ADC for the neoadjuvant treatment of HER2 positive breast cancer Aktis Oncology announces FDA clearance of Investigational New Drug applications for AKY-2519 NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development Monthly Digest – April 2026 Monthly Digest – April 2026